مباشر
FierceBiotechJ&J makes $1B upfront bet on emerging DAC space by netting Firefly BioEndpoints NewsGSK inks multi-target pact with Engitix; Sangamo considers strategic optionsEndpoints NewsTango plans Phase 3 pancreatic cancer study after combo successEndpoints NewsComing SoonEndpoints NewsBiopharma's top-paid CEOs of 2025: 25 making $25M+Endpoints NewsCavalry Biosciences pursues $75M Series B to test eye and muscle disorder drugsFierceBiotechBiopharma moves to reduce development risk earlier than everFierceBiotechIncyte inks $2B deal to add Star unit to late-phase constellation and challenge TakedaEndpoints News#ADA26: Novo Nordisk targets 2030 launch for triple-G obesity shotFierceBiotechWhy Execution Excellence Now Defines Biopharma WinnersFierceBiotechHow integrated strategy is reshaping biopharma growthFierceBiotechBiotech value creation at an inflection point
BioWorld ٣١ ديسمبر ٢٠٢٥

Corcept looks to ovarian cancer as relacorilant gets CRL in Cushing

Corcept looks to ovarian cancer as relacorilant gets CRL in Cushing

المصدر
المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.